Newsbenzinga
Summit Therapeutics Flags Going Concern Risk Over Cash Needs
· Published
Article summary
Summit Therapeutics beat second-quarter estimates but warned current cash is insufficient to fund operations for the next year.
An excerpt from the original article.
Comments —
Loading comments…